Drexler H G, MacLeod R A, Uphoff C C
Leuk Res. 1999 Mar;23(3):207-15. doi: 10.1016/s0145-2126(98)00171-4.
The Philadelphia (Ph) chromosome, the main product of the (9;22)(q34;q11) translocation, is the cytogenetic hallmark of chronic myeloid leukemia (CML), a clonal myeloproliferative disorder of the hematopoietic stem cell; the Ph chromosome is also found in a sizeable portion of acute lymphoblastic leukemia (ALL) patients and in a small number of acute myeloid leukemia (AML) cases. At the molecular level, the t(9;22) leads to the fusion of the BCR gene (on chromosome 22) to the ABL gene (translocated from chromosome 9); this fusion gene BCR-ABL with its elevated tyrosine kinase activity must to be central to the pathogenesis of these disorders. Three different breakpoint cluster regions are discerned within the BCR gene on chromosome 22: M-bcr, m-bcr, and mu-bcr. Ph + leukemia cell lines are important tools in this research area. More than 20 ALL-and more than 40 CML-derived Ph + leukemia cell lines have been described. Furthermore, three Ph + B-lymphoblastoid cell lines, established from patients with Ph + ALL or CML, are available. Molecular analysis has documented BCR-ABL fusion genes in three apparently Ph chromosome-negative cell lines, all three derived from CML. Nearly all Ph + ALL cell lines have the m-bcr e1-a2 fusion gene (only two ALL cell lines have a b3-a2 fusion) whereas all CML cell lines, but one carry the M-bcr b2-a2, b3-a2 or both hybrids. The mu-bcr e19-a2 has been detected in one CML cell line. Four cell lines display a three-way translocation involving chromosomes 9, 22 and a third chromosome. Additional Ph chromosomes (up to five) have been found in four Ph + ALL cell lines and in 18 CML cell lines; though in some cell lines the extra Ph chromosome(s) might be caused by the polyploidy (tri- and tetraploidy) of the cells. Another modus to acquire additional copies of the BCR-ABL fusion gene is the formation of tandem repeats of the BCR-ABL hybrid as seen in CML cell line K-562. Both mechanisms, selective multiplication of the der(22) chromosome and tandem replication of the fusion gene BCR-ABL, presumably lead to enhanced levels of the fusion protein and its tyrosine kinase activity (genetic dosage effect). The availability of a panel of Ph + cell lines as highly informative leukemia models offers the unique opportunity to analyze the pathobiology of these malignancies and the role of the Ph chromosome in leukemogenesis.
费城(Ph)染色体是(9;22)(q34;q11)易位的主要产物,是慢性髓性白血病(CML)的细胞遗传学标志,CML是一种造血干细胞的克隆性骨髓增殖性疾病;在相当一部分急性淋巴细胞白血病(ALL)患者以及少数急性髓性白血病(AML)病例中也发现了Ph染色体。在分子水平上,t(9;22)导致BCR基因(位于22号染色体上)与ABL基因(从9号染色体易位而来)融合;这种具有升高的酪氨酸激酶活性的融合基因BCR-ABL必定是这些疾病发病机制的核心。在22号染色体上的BCR基因内可识别出三个不同的断裂点簇区域:M-bcr、m-bcr和μ-bcr。Ph +白血病细胞系是该研究领域的重要工具。已经描述了20多种ALL来源和40多种CML来源的Ph +白血病细胞系。此外,还有三种从Ph + ALL或CML患者建立的Ph + B淋巴母细胞系。分子分析已在三个明显Ph染色体阴性的细胞系中记录到BCR-ABL融合基因,这三个细胞系均源自CML。几乎所有Ph + ALL细胞系都有m-bcr e1-a2融合基因(只有两个ALL细胞系有b3-a2融合),而所有CML细胞系,但有一个携带M-bcr b2-a2、b3-a2或两者的杂种。在一个CML细胞系中检测到μ-bcr e19-a2。四个细胞系显示涉及9号、22号染色体和第三条染色体的三向易位。在四个Ph + ALL细胞系和18个CML细胞系中发现了额外的Ph染色体(多达五条);尽管在一些细胞系中,额外的Ph染色体可能是由细胞的多倍体(三倍体和四倍体)引起的。获得BCR-ABL融合基因额外拷贝的另一种方式是形成BCR-ABL杂种的串联重复,如在CML细胞系K-562中所见。这两种机制,即der(22)染色体的选择性增殖和融合基因BCR-ABL的串联复制,大概会导致融合蛋白及其酪氨酸激酶活性水平升高(基因剂量效应)。一组Ph +细胞系作为信息丰富的白血病模型的可用性提供了独特的机会来分析这些恶性肿瘤的病理生物学以及Ph染色体在白血病发生中的作用。